Skip to main content

BioDelivery Sciences International Value Stock - Dividend - Research Selection

BioDelivery Sciences International

ISIN: US09060J1060, WKN: 766464

Market price date: 28.05.2021
Market price: 3,53 USD

BioDelivery Sciences International Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-03-2021
Cash flow
Net operating cash flow 24.981.000
Capital Expenditures -13.000
Free cash flow 24.968.000
Balance sheet
Total Equity 108.234.000
Liabilities & Shareholders equity 239.894.000
Income statement
Net income 25.711.000
Eps (diluted) 0,240
Diluted shares outstanding 107.129.000
Net sales/revenue 156.471.000

Fundamental ratios calculated on: 28-05-2021

Key figures 28-05-2021
Cash flow
P/C 15,14
P/FC 15,15
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization378.165.376,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company. BDSI is developing and commercializing, either on its own or in partnerships with third parties, applications of therapeutics to address medical needs. The Company has developed and is continuing to develop pharmaceutical products aimed principally in the areas of pain management and oncology supportive care. In formulating the Company´s products and product candidates, BDSI utilizes the BioErodible MucoAdhesive (BEMA) drugs delivery technology, a small, erodible polymer film for application to the buccal mucosa. The Company´s the United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its pipeline of product candidates, utilize its BEMA technology.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,